MVASI 400 mg/16mL
bevacizumab-awwb · INJECTION, SOLUTION · Amgen, Inc
No Recall History
Plain English
MVASI is a injection, solution containing bevacizumab-awwb at 400 mg/16mL, taken intravenous. Manufactured by Amgen, Inc.
Key Facts
- Brand Name
- MVASI
- Generic Name
- bevacizumab-awwb
- NDC Code (Product)
55513-207- Manufacturer
- Amgen, Inc
- Strength
- 400 mg/16mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761028
- Drug Class
- Vascular Endothelial Growth Factor Inhibitor [EPC]
- Marketing Start
- 06/01/2018
Recall History
No Recall HistoryFrequently Asked Questions
What is MVASI used for?
MVASI contains bevacizumab-awwb. It is a injection, solution taken intravenous. Consult your doctor for specific uses.
Is MVASI a controlled substance?
MVASI is not classified as a controlled substance by the DEA.
What is the generic name for MVASI?
The generic name for MVASI is bevacizumab-awwb. There are no other listed brand versions of bevacizumab-awwb.
What is the NDC code for MVASI 400 mg/16mL?
The NDC (National Drug Code) for MVASI 400 mg/16mL is 55513-207, listed by Amgen, Inc.
Other MVASI Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)